<DOC>
	<DOCNO>NCT01435122</DOCNO>
	<brief_summary>The main purpose study see whether Axitinib help prolong time patient 's carcinoid tumor remain stable , examine treatment response test . Researchers also want find Axitinib safe tolerable .</brief_summary>
	<brief_title>A Study Axitinib Advanced Carcinoid Tumors</brief_title>
	<detailed_description>This bi-institutional , prospective phase II , open-label study . The target population comprise adult patient histologically confirm unresectable metastatic carcinoid tumor . Carcinoid tumor define well moderately differentiate neuroendocrine tumor digestive tract lung . Patients metastatic carcinoid tumor unknown primary well rare primary ( renal , ovarian , thymic , hepatic ) also eligible . Patients draw two institution Moffitt Cancer Center ( MCC ) The University California , San Francisco ( UCSF ) .</detailed_description>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Locally unresectable metastatic welland moderatelydifferentiated ( low intermediate grade ) neuroendocrine tumor aerodigestive tract ( e.g . foregut , midgut , hindgut ) unknown primary site well rare primary site ( renal , ovarian , thymic , hepatic ) ; Otherwise know typical atypical carcinoid tumor Measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) Criteria Functional nonfunctional tumor allow Evidence progressive disease within 12 month study entry Adequate hepatic function : total bilirubin ≤1.5 x upper limit normal ( ULN ) mg/dl ; aspartic transaminase ( AST ) ≤2.5 x ULN ( ≤5 x ULN attributable liver metastasis ) Adequate renal function : serum creatinine ≤ 1.5 x ULN Adequate bone marrow function : absolute neutrophil count ≥ 1,500/mm³ ; platelet ≥75,000/mm³ Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) level ≤1.5 x ULN ( unless patient receive coumadin anticoagulation case stable international normalization ration ( INR ) 23 require ) . Urine protein &lt; 2+proteinuria ( &lt; 2 g proteinuria /24 hr ) Prior somatostatinanalog therapy require patient midgut carcinoid tumor Minimum 4 week since completion prior treatment ( investigational ) . Prior treatment chemotherapy , radiotherapy , hepatic artery embolization , surgery therapeutic agent allow . Treatment related toxicity return baseline and/or ≤grade 1 prior study treatment . Prior concurrent therapy somatostatin analog permit control hormonemediated symptom , provide patient stable dose least 2 month progressive disease somatostatin analog ( SSTa ) document Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Women childbearing potential must negative serum pregnancy test within 14 day prior treatment . Ability sign inform consent Willingness ability comply schedule visit , laboratory test study procedure Poorly differentiate , highgrade ( e.g . small cell large cell ) neuroendocrine carcinoma exclude . Pancreatic neuroendocrine tumor ( NETs ) , paragangliomas , pheochromocytomas medullary thyroid cancer exclude . Adenocarcinoid tumor goblet cell carcinoid tumor exclude . Prior antiangiogenic therapy dedicate vascular endothelial growth factor ( VEGF ) pathway inhibitor Clinically apparent central nervous system metastases Any follow within 12 month prior study : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack Deep venous thrombosis pulmonary embolism within 6 month study Major surgery 4 week prior enrollment Inability take oral medication prior surgical procedure affect absorption ( include total gastric resection ) Active gastrointestinal bleeding , transfusion dependent History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day History pulmonary hemorrhage evidence significant hemoptysis History serious nonhealing wound , ulcer , bone fracture within past 28 day Preexisting thyroid abnormality allow provide thyroid function control medication . Current use anticipate need treatment drug know potent CYP3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , etc . ) Current use anticipate need treatment drug know inducer CYP3AR CYP1A2 ( i.e carbamazepine , dexamethasone , omeprazole , phenobarbital , phenytoin , rifampin , St. John 's Wart , etc . ) Uncontrolled serious medical psychiatric illness . Patients `` currently active '' second malignancy nonmelanoma skin cancer , carcinoma situ cervix , resect incidental prostate cancer ( stag pathological tumor2 ( pT2 ) Gleason Score ≤ 6 postoperative prostatic specific antigen ( PSA ) &lt; 0.5 ng/mL ) , adequately treat carcinomainsitu ineligible . Patients consider `` currently active '' malignancy complete therapy free disease ≥3 year . Pregnant lactate woman , adult reproductive potential use effective birthcontrol method . Prior antitumor therapy within 4 week enrollment ( exception somatostatin analog ) Liverdirected therapy within 2 month enrollment . Prior treatment radiotherapy ( include radiolabeled sphere and/or cyberknife , hepatic arterial embolization ( without chemotherapy ) cryotherapy/ablation allow therapy affect area measurable disease use protocol progressive disease document previously treat area . Recent infection require systemic antiinfective treatment complete ≤14 day prior enrollment ( exception uncomplicated urinary tract infection upper respiratory tract infection ) Uncontrolled hypertension ( bloodpressure &gt; 140/90 ) . Patient baseline hypertension may eligible initiation antihypertensive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>progressive advance carcinoid tumor</keyword>
	<keyword>advanced</keyword>
	<keyword>unresectable</keyword>
	<keyword>metastatic</keyword>
	<keyword>cancerous tumor</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>digestive tract</keyword>
	<keyword>lung</keyword>
	<keyword>renal</keyword>
	<keyword>ovarian</keyword>
	<keyword>thymic</keyword>
	<keyword>hepatic</keyword>
</DOC>